Organization
Eidos Therapeutics
4 clinical trials
Clinical trial
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201Status: Active (not recruiting), Estimated PCD: 2027-07-01
Clinical trial
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)Status: Active (not recruiting), Estimated PCD: 2028-04-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid CardiomyopathyStatus: Completed, Estimated PCD: 2018-10-05